Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Lemtrada
|
| gptkbp:activities |
targets C D52 antigen
|
| gptkbp:appointed_by |
gptkb:hospital
intravenous infusion |
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:associated_with |
cytokine release syndrome
risk of secondary malignancies |
| gptkbp:clinical_trial |
Phase II
Phase III off-label for multiple sclerosis |
| gptkbp:contraindication |
hypersensitivity to alemtuzumab
|
| gptkbp:developed_by |
Berlex Laboratories
|
| gptkbp:discontinued |
some markets
|
| gptkbp:dosage_form |
daily for 5 days
|
| gptkbp:has_impact_on |
lymphocyte populations
|
| https://www.w3.org/2000/01/rdf-schema#label |
Campath
|
| gptkbp:indication |
B-cell malignancies
|
| gptkbp:influenced_by |
genetic factors
|
| gptkbp:influences |
immune response
|
| gptkbp:ingredients |
C646 H1008 N178 O198 S4
|
| gptkbp:interacts_with |
vaccines
immunosuppressants |
| gptkbp:invention |
patented
|
| gptkbp:involves |
patient education
|
| gptkbp:is_analyzed_in |
other autoimmune diseases
|
| gptkbp:is_available_in |
various formulations
|
| gptkbp:is_available_on |
lyophilized powder
|
| gptkbp:is_considered |
orphan drug
|
| gptkbp:is_evaluated_by |
clinical trials
|
| gptkbp:is_known_for |
gptkb:alemtuzumab
|
| gptkbp:is_linked_to |
immunological effects
|
| gptkbp:is_monitored_by |
blood counts
|
| gptkbp:is_part_of |
treatment regimens
cancer treatment protocols |
| gptkbp:is_subject_to |
post-marketing surveillance
|
| gptkbp:is_used_for |
treatment of chronic lymphocytic leukemia
|
| gptkbp:is_used_in |
hematological malignancies
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:marketed_as |
gptkb:brand
|
| gptkbp:pharmacokinetics |
long half-life
depletes T and B lymphocytes |
| gptkbp:population |
adults
|
| gptkbp:provides_information_on |
NCCN guidelines
|
| gptkbp:replaced_by |
other therapies
|
| gptkbp:requires |
pre-medication
|
| gptkbp:research_focus |
gptkb:vaccine
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:fandom
infections thrombocytopenia autoimmune disorders infusion reactions neutropenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitable_for |
pregnant women
lactating women |
| gptkbp:used_in |
combination therapy
|
| gptkbp:weight |
150 k Da
|